Patents Assigned to Biomedicines, Inc.
-
Patent number: 11932694Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: April 19, 2018Date of Patent: March 19, 2024Assignee: Bluefin BioMedicine, Inc.Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
-
Publication number: 20230355676Abstract: An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof: (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.Type: ApplicationFiled: May 12, 2023Publication date: November 9, 2023Applicants: GAIA BioMedicine INC.Inventors: Yoshikazu Yonemitsu, Yui Harada, Koji Teraishi
-
Publication number: 20230256019Abstract: The object of the invention is to stably bind an antibody to NK cells. A method for stabilizing binding of an antibody and an NK cell is provided, which method uses a substance having a region I that can bind to a surface protein of the NK cell, and a region II that can bind to the antibody. The substance may further contain a linker portion for linkage in addition to the region I and the region II.Type: ApplicationFiled: June 30, 2021Publication date: August 17, 2023Applicant: GAIA BioMedicine INC.Inventors: Yui Harada, Yoshikazu Yonemitsu
-
Patent number: 11723924Abstract: An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof. (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.Type: GrantFiled: May 11, 2018Date of Patent: August 15, 2023Assignees: GAIA BioMedicine Inc.Inventors: Yoshikazu Yonemitsu, Yui Harada, Koji Teraishi
-
Patent number: 11702481Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.Type: GrantFiled: December 15, 2017Date of Patent: July 18, 2023Assignee: Bluefin Biomedicine, Inc.Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
-
Patent number: 11634486Abstract: Disclosed herein are anti-Seizure Related 6 Homolog Like 2 (SEZ6L2) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: December 22, 2017Date of Patent: April 25, 2023Assignee: Bluefin BioMedicine, Inc.Inventors: Kevin Jefferies, Scott Michael Lonning, Nels Eric Pederson, Jason G. Beaudet, Klarisa Rikova, Aleksandr Tkachev
-
Patent number: 11628167Abstract: The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.Type: GrantFiled: May 3, 2022Date of Patent: April 18, 2023Assignee: Endeavor Biomedicines, Inc.Inventors: Miguel de los Rios, John Hood, Anita Difrancesco
-
Publication number: 20230109717Abstract: The object is to provide a method for cryopreserving and thawing cells with maintaining high viability and high activity, which is applicable to highly active NK cells. A method for treating cells, which comprises the following steps of: (1) collecting in vitro-activated cells in a medium for cell culture; (2) suspending the collected cells in a solution for cryopreservation; and (3) freezing the suspended cells. The step (1) preferably includes a treatment with a medium supplemented with any selected from the group consisting of a bile acid and phenylbutyric acid.Type: ApplicationFiled: March 2, 2021Publication date: April 13, 2023Applicant: GAIA BioMedicine Inc.Inventors: Yui Harada, Yoshikazu Yonemitsu
-
Publication number: 20230069760Abstract: Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: ApplicationFiled: April 19, 2018Publication date: March 2, 2023Applicants: Bluefin BioMedicine, Inc., Bluefin BioMedicine, Inc.Inventors: Ailan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
-
Patent number: 11434303Abstract: Disclosed herein are anti-lymphocyte antigen 6 complex, locus H (LY6H) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: June 28, 2018Date of Patent: September 6, 2022Assignee: Bluefin BioMedicine, Inc.Inventors: Tinglei Gu, Scott Michael Lonning, Nels Eric Pederson, Aleksandr Tkachev, Klarisa Rikova, Sean A. Beausoleil
-
Patent number: 11400092Abstract: The present disclosure provides methods of mitigating thiamine deficiency.Type: GrantFiled: December 23, 2021Date of Patent: August 2, 2022Assignee: Impact Biomedicines, Inc.Inventors: Tymara Berry, John Hood, Catriona Jamieson, Curtis L. Scribner
-
Publication number: 20220184122Abstract: An object is to quickly provide immune cells to a recipient. A system for providing immune cells obtained from a donor (non-recipient) to a recipient, which comprises the following steps: the step of preparing a formulation of immune cells collected from a donor in a unit suitable for administration; the step of performing an evaluation test on the formulation; the step of refrigerating or freezing the formulation and stocking it with immune type information of the donor; and the step of selecting a formulation suitable for the recipient from stocked formulations subjected to the evaluation test or identifying a recipient suitable for one selected stocked formulation subjected to the evaluation test.Type: ApplicationFiled: March 19, 2020Publication date: June 16, 2022Applicants: GAIA BioMedicine Inc.Inventors: Yui Harada, Yoshikazu Yonemitsu, Kazuyuki Kuramori
-
Patent number: 11312769Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: March 22, 2018Date of Patent: April 26, 2022Assignee: Bluefin BioMedicine, Inc.Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
-
Patent number: 11267886Abstract: Disclosed herein are anti-immunoglobulin-like transcript-3 (ILT3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: February 9, 2018Date of Patent: March 8, 2022Assignee: Bluefin BioMedicine, Inc.Inventors: Jaime Darce, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev
-
Patent number: 11248054Abstract: Disclosed herein are Interleukin 1 Receptor Accessory Protein (IL1RAP) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: GrantFiled: June 12, 2018Date of Patent: February 15, 2022Assignee: BLUEFIN BIOMEDICINE, INC.Inventors: Tinglei Gu, Scott Michael Lonning, Jason G. Beaudet, Sean A. Beausoleil, Nels Eric Pederson, Daniel Mulhern
-
Publication number: 20210330707Abstract: An NK cell showing higher cytotoxic activity is provided. An object of the present invention is to provide a pharmaceutical composition for NK cell therapies expected to be highly effective. The present invention provides an NK cell having the following characteristics of (1) and (2) or a population thereof. (1) the NK cell is CD16-positive, highly expresses CD56, and is CD57-negative, and (2) the NK cell is NKG2C-positive, is NKG2A-negative or lowly expresses NKG2A, and is CD94-positive. The present invention also provides a pharmaceutical composition containing a population of such NK cells, and a therapeutically effective amount of antibodies.Type: ApplicationFiled: May 11, 2018Publication date: October 28, 2021Applicants: GAIA BioMedicine Inc.Inventors: Yoshikazu Yonemitsu, Yui Harada, Koji Teraishi
-
Publication number: 20210095250Abstract: The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells. The present invention provides the cell population, wherein the CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells further highly express CD11c. The present invention provides a CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cell, which infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition containing such a cell population and a pharmaceutically acceptable additive. The present invention further provides a method for producing the aforementioned cell population.Type: ApplicationFiled: March 26, 2019Publication date: April 1, 2021Applicants: GAIA BioMedicine Inc.Inventors: Yoshikazu Yonemitsu, Yui Harada
-
Publication number: 20210000871Abstract: An object of the present invention is to provide an effective method for producing a population of NK cells for cell therapy. Another object of the present invention is to improve in vitro amplification efficiency of NK cells. A still another object of the present invention is to flexibly increase signals required for licensing of NK cells. There is provided a method for producing a cell population including NK cells, which comprises preparing a cell population of mononuclear cells originating in a plurality of donors and including NK cells, and incubating the prepared population of mononuclear cells under conditions effective for treating and proliferating NK cells to proliferate NK cells.Type: ApplicationFiled: March 4, 2020Publication date: January 7, 2021Applicant: GAIA BioMedicine Inc.Inventors: Yoshikazu Yonemitsu, Yui Harada
-
Publication number: 20200109194Abstract: Disclosed herein are transmembrane protein with EGF-like and two-follistatin-like domains 1 (TMEFF1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.Type: ApplicationFiled: March 22, 2018Publication date: April 9, 2020Applicant: Bluefin BioMedicine, Inc.Inventors: Isabel Milan Chu, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Jason G. Beaudet
-
Publication number: 20200061276Abstract: An object of the present invention is to provide an artificial liver using highly functional hepatocytes. There is provided an extracorporeal artificial liver having at least one module comprising the followings: a plasma ingredient inlet port, and a plasma ingredient outlet port; a plasma ingredient circulation chamber having the plasma ingredient inlet port, and the plasma ingredient outlet port; and a hepatocyte culture chamber provided adjacently to the plasma ingredient circulation chamber and separated from the plasma ingredient circulation chamber with a separation membrane through which ammonia can permeate, but hepatocytes cannot permeate, in which hepatocytes having an ammonia-metabolizing ability are cultured.Type: ApplicationFiled: April 27, 2018Publication date: February 27, 2020Applicants: GAIA BioMedicine Inc.Inventors: Yoshikazu Yonemitsu, Yui Harada